Variant Interpretation in Patients With Metastatic Breast Cancer

To the Editor We read with great interest the study by Stuttgen and colleagues¹ assessing pathogenic germline variants in patients with metastatic breast cancer. The approval of 2 polyadenosine diphosphate–ribose polymerase inhibitors by the US Food and Drug Administration in 2018 opened a promising therapeutic potential for patients with metastatic breast cancer with germline pathogenic BRCA1 and BRCA2 variants. To our knowledge, there are no studies evaluating the prevalence of pathogenic/likely pathogenic (P/LP) variants in such patients by the use of multigene panels. The concept of the study published by Stuttgen and colleagues¹ is novel and kick-starts an era of similar studies to follow.